Minerva Neurosciences (NERV) EBT Margin (2020)
Minerva Neurosciences (NERV) posted EBT Margin of 71.21% for Q2 2020.
Minerva Neurosciences (NERV) EBT Margin (2020) Analysis & Trends
Minerva Neurosciences' EBT Margin history runs 1 years deep, the most recent figure standing at 71.21% for Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,741.39 Bn | 66,741.11 Bn | - | - |
| 2 | Nanobiotix | 1,913.26 Bn | 1,913.20 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.02 Bn | 466.23 Bn | 1.35 Bn | 17.13% |
| 5 | Vertex Pharmaceuticals | 122.17 Bn | 114.92 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 69.85 Bn | 61.10 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.60 Bn | 50.42 Bn | 1.41 Bn | 34.77% |
| 9 | Alnylam Pharmaceuticals | 37.39 Bn | 34.38 Bn | 959.66 Mn | 18.99% |
| 10 | Minerva Neurosciences | 184.38 Mn | 184.38 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | 71.21% |